Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B

Seminars in Hematology

Volumn 43, Issue 4, 2006, Pages 240-250

  Nademanee, Auayporn ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; IBRITUMOMAB TIUXETAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; TENIPOSIDE; TOSITUMOMAB I 131; VINCRISTINE; VINDESINE;

ACUTE LEUKEMIA; ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIFFUSE LARGE B CELL LYMPHOMA B; DISEASE DURATION; DISEASE SEVERITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HUMAN; INFECTION COMPLICATION; LUNG DISEASE; MAINTENANCE THERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYELODYSPLASIA; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOTHERAPY; THERAPY EFFECT; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; RADIOIMMUNOTHERAPY; RECURRENCE; SURVIVAL ANALYSIS;

EID: 33749249251     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.07.006     Document Type: Article

References (52)

1. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van Der Lelie H., Bron D., et al. Autologous Bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
2. Haioun C., Lepage E., Gisselbrecht C., Bastion Y., Coiffier B., Brice P., et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 15 (1997) 1131-1137
3. Weaver C.H., Petersen F.B., Appelbaum F.A., Bensinger W.I., Press O., Martin P., et al. High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 12 (1994) 2559-2566
4. Horning S.J., Negrin R.S., Chao N.J., Long G.D., Hoppe R.T., and Blume K.G. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12 (1994) 2552-2558
5. Stiff P.J., Unger J.M., Forman S.J., McCall A.R., LeBlanc M., Nademanee A.P., et al. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 9 (2003) 529-539
6. Gutierrez-Delgado F., Maloney D.G., Press O.W., Golden J., Holmberg L.A., Maziarz R.T., et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: Comparison of radiation-based and chemotherapuy-only preparative regimens. Bone Marrow Transplant 28 (2001) 455-461
7. Brown J.R., Yeckes H., Friedberg J.W., Neuberg D., Kim H., Nadler L.M., et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 2208-2214
8. Darrington D.L., Vose J.M., Anderson J.R., Bierman P.J., Bishop M.R., Chan W.C., et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogeneous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12 (1994) 2527-2534
9. Blay J., Gomez F., Sebban C., Bachelot T., Biron P., Guglielmi C., et al., Parma Group. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: Analysis of the PARMA trial. Blood 92 (1998) 3562-3568
10. Guglielmi C., Gomez F., Philip T., Hagenbeek A., Martelli M., Sebban C., et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol 16 (1998) 3264-3269
11. Hamlin P.A., Zelenetz A.D., Kewalramani T., Qin J., Satagopan J.M., Verbel D., et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102 (2003) 1989-1996
12. Spaepen K., Stroobants S., Dupont P., Vandenberghe P., Maertens J., Bormans G., et al. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood 102 (2003) 53-59
13. Alousi A.M., Saliba R.M., Okoroji G., Hosing C., Samuels B.I., Champlin R.E., et al. The influence of PET/gallium (P/G) status and high-dose rituximab (HDR) in patients (pts) with aggressive, large, B-cell lymphoma (LBCL) receiving autologous stem cell transplants (ASCT). J Clin Oncol (Meeting Abstracts) 24 (2006) 6518 (abstr)
14. Cortelazzo S., Rambaldi A., Rossi A., Oldani E., Ghielmini M., Benedetti F., et al. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma. Br J Haematol 114 (2001) 333-341
15. Josting A., Sieniawski M., Glossmann J.P., Staak O., Nogova L., Peters N., et al. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a multicenter phase II study. Ann Oncol 16 (2005) 1359-1365
16. Coiffier B., Lepage E., Briere J., Herbrecht R., Tilly H., Bouabdallah R., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
17. Pfreundschuh M., Trumper L., Osterborg A., Pettengell R., Trneny M., Imrie K., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good prognosis diffuse large B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
18. Kewalramani T., Zelenetz A.D., Nimer S.D., Portlock C., Straus D., Noy A., et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103 (2004) 3684-3688
19. Khouri I.F., Saliba R.M., Hosing C., Okoroji G.J., Acholonu S., Anderlini P., et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23 (2005) 2240-2247
20. Horwitz S.M., Negrin R.S., Blume K.G., Breslin S., Stuart M.J., Stockerl-Goldstein K.E., et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 103 (2004) 777-783
21. Rapoport A.P., Meisenberg B., Sarkodee-Adoo C., Fassas A., Frankel S.R., Mookerjee B., et al. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 29 (2002) 303-312
22. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger C.C., Nelp W.B., et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329 (1993) 1219-1224
23. Press O.W., Eary J.F., Gooley T., Gopal A.K., Liu S., Rajendran J.G., et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96 (2000) 2934-2942
24. Nademanee A., Forman S., Molina A., Fung H., Smith D., Dagis A., et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106 (2005) 2896-2902
25. Vose J.M., Bierman P.J., Enke C., Hankins J., Bociek G., Lynch J.C., et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 461-467
26. Winter J.N., Inwards D., Erwin W., Wiseman G., Rademaker A., Patton D.R., et al. Zevalin dose-escalation foolowed by high-dose BEAM and autologous peripheral blood progenitor cell (PBPC) transplant in non-Hodgkin's lymphoma: Early outcome results. Blood 100 (2002) 411a (abstr)
27. Krishnan A.Y., Nademanee A., Forman S.J., Fung H., Molina A., Yamauchi D., et al. The outcome of ZBEAM, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin's lymphoma (NHL). J Clin Oncol (Meeting Abstracts) 23 (2005) 6566 (abstr)
28. Santini G., Salvagno L., Leoni P., Chisesi T., De Souza C., Sertoli M.R., et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 16 (1998) 2796-2802
29. Milpied N., Deconinck E., Gaillard F., Delwail V., Foussard C., Berthou C., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350 (2004) 1287-1295
30. Gisselbrecht C., Lepage E., Molina T., Quesnel B., Fillet G., Lederlin P., et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20 (2002) 2472-2479
31. Kaiser U., Uebelacker L., Abel U., Birkmann J., Trümper L., Schmalenberg H., et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol 20 (2002) 4413-4419
32. Martelli M., Gherlinzoni F., De Renzo A., Zinzani P.L., de Vivo A., Cantonetti M., et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial. J Clin Oncol 21 (2003) 1255-1262
33. Kluin-Nelemans H.C., Zagonel V., Anastasopoulou A., Bron D., Roozendaal K.J., Noordijk E.M., et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: Randomized phase III EORTC study. J Natl Cancer Inst 93 (2001) 22-30
34. Gopal A.K., Gooley T.A., Golden J.B., Maloney D.G., Bensinger W.I., and Petersdorf S.H. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 27 (2001) 593-599
35. Jantunen E., Itala M., Juvonen E., Leppa S., Keskinen L., Vasala K., et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: A nation-wide analysis. Bone Marrow Transplant 37 (2006) 367-372
36. Peniket A.J., De Elvira M.C.R., Taghipour G., Cordonnier C., Gluckman E., De Witte T., et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: Allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31 (2003) 667-678
37. Freytes C.O., Loberiza F.R., Rizzo J.D., Bashey A., Bredeson C.N., Cairo M.S., et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood 104 (2004) 3797-3803
38. Robinson S.P., Goldstone A.H., Mackinnon S., Carella A., Russell N., de Elvira C.R., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100 (2002) 4310-4316
39. Rodriguez R, Nademanee A, Carter N, Smith E, Krishnan A, Popplewell L, et al: Comparison of reduced intensity with conventional myeloablative regimens for allogeneic transplant of non-Hodgkin lymphoma. (submitted for publication)
40. Mackinnon S. Reduced intensity allogeneic stem cell transplantation for relapsed Hodgkin and non-Hodgkin's lymphoma lowers regimen toxicity and facilitates a graft-versus-lymphoma effect. Ann Oncol 16 (2005) v34 (abstr)
41. Moskowitz C.H., Bertino J.R., Glassman J.R., Hedrick E.E., Hunte S., Coady-Lyons N., et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3776-3785
42. Velasquez W.S., Cabanillas F., Salvador P., McLaughlin P., Fridrik M., and Tucker S. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71 (1988) 117-122
43. Velasquez W.S., McLaughlin P., Tucker S., Hagemeister F.B., Swan F., Rodriguez M.A., et al. ESHAP-An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4 year follow-up study. J Clin Oncol 12 (1994) 1169-1176
44. Cabanillas F., Hagemeister F.B., McLaughlin P., Velasquez W.S., Riggs S., Fuller L., et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 5 (1987) 407-412
45. Johnstone R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1 (2002) 287-299
46. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., William R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24 (2006) 166-173
47. Moskowitz C.H. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. Ann Oncol 17 (2006) iv37-iv39
48. Gillies S.D., Lan Y., Williams S., Carr F., Forman S., Raubitschek A., et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105 (2005) 3972-3978
49. Cooper L.J., Kalos M., DiGiusto D., Brown C., Forman S.J., Raubitschek A., et al. T-cell genetic modification for re-directed tumor recognition. Cancer Chemother Biol Response Modif 22 (2005) 293-324
50. Jensen M. Strategies to enhance the therapeutic efficacy of autologous hematopoietic stem cell transplantation by posttransplantation adoptive transfer of T cells with engineered graft-versus-tumor activity. Biol Blood Marrow Transplant 11 (2005) 34-39
51. Gianni A.M., Bregni M., Siena S., Brambilla C., Nicola M.D., Lombardi F., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336 (1997) 1290-1297
52. Olivieri A., Santini G., Patti C., Chisesi T., De Souza C., Rubagotti A., et al. Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: Long-term results by the NHLCSG. Ann Oncol 16 (2005) 1941-1948